Estrella, B., Liu, Y., Ricker, E. C., Pazos, M. A., Fiorito, J., Zuccarello, E., Calcagno, E., Honig, B., Arancio, O., & Amengual, J. E. (2021). Histone Acetyltransferase (HAT) Activator, YF2, Modulates the p53:BCL6 Axis and Antigen Presentation in Diffuse Large B-Cell Lymphomas. Blood, 138(Supplement 1), 2254–2254. https://doi.org/10.1182/blood-2021-151442

Zonder, J. A., Richter, J., Bumma, N., Brayer, J., Hoffman, J. E., Bensinger, W. I., Wu, K. L., Xu, L., Chokshi, D., Boyapati, A., Sharma, M., Rodriguez Lorenc, K., Kroog, G. S., Dhodapkar, M. V., Lentzsch, S., Cooper, D., & Jagannath, S. (2021). Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome with REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 First-in-Human Study in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 138(Supplement 1), 160–160. https://doi.org/10.1182/blood-2021-144921

Baljevic, M., Gasparetto, C., Schiller, G. J., Tuchman, S. A., Callander, N. S., Lentzsch, S., Monge, J., Kotb, R., Bahlis, N. J., White, D., Chen, C. I., Sutherland, H. J., Madan, S., Leblanc, R., Sebag, M., Venner, C. P., Bensinger, W. I., Biran, N., DeCastro, A., … Lipe, B. (2021). Selinexor-Based Regimens in Patients with Multiple Myeloma after Prior Anti-B-Cell Maturation Antigen Treatment. Blood, 138(Supplement 1), 2751–2751. https://doi.org/10.1182/blood-2021-150998

Bahlis, N. J., Richard, S., White, D. J., Grosicki, S., Chen, C., Delimpasi, S., Sutherland, H. J., Maslyak, Z., Sebag, M., Gavriatopoulou, M., Lentzsch, S., Chari, A., Simonova, M., Spicka, I., Kriachok, I., Dimopoulos, M. A., Pylypenko, H., Auner, H. W., Leleu, X., … Richardson, P. G. (2021). Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd). Blood, 138(Supplement 1), 1634–1634. https://doi.org/10.1182/blood-2021-146324

Srisuwananukorn, A., Percha, B., Abu-Zeinah, G., Scandura, J., Krichevsky, S., Taylor, E., Silver, R. T., Thibaud, S., Ronner, L., Podoltsev, N., Gotlib, J., Heaney, M. L., Kuykendall, A. T., O’Connell, C., Shammo, J. M., Fleischman, A., Mesa, R. A., Yacoub, A., Hoffman, R., … Tremblay, D. (2021). Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily-Available Baseline Characteristics. Blood, 138(Supplement 1), 2583–2583. https://doi.org/10.1182/blood-2021-150561

Li, S., Fu, J., Yang, J., Ma, H., Mapara, M. Y., Marcireau, C., & Lentzsch, S. (2021). MAP4K2 Silencing Overcomes IMiDs-Resistance in Multiple Myeloma. Blood, 138(Supplement 1), 2662–2662. https://doi.org/10.1182/blood-2021-151844

Chakraborty, R., Yan, Y., & Royal, M. (2021). A Phase 1, Open-Label, Dose-Escalation Study of the Safety and Efficacy of Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients with Relapsed or Refractory Multiple Myeloma. Blood, 138(Supplement 1), 4763–4763. https://doi.org/10.1182/blood-2021-150783